from the TAXUS V de novo (DN) clinical trial, evaluating the long-term
safety and clinical efficacy of the TAXUS Express2 Paclitaxel-Eluting
Coronary Stent System versus bare-metal stents in complex patient
populations, including small vessel lesions, long lesions, diabetics
and multiple stents. The TAXUS V DN trial is a prospective,
randomized, double-blind trial that has enrolled 1,172 patients at 66
sites in the U.S. The results will be presented by Stephen G. Ellis,
M.D., at an oral abstract session at 3:45 p.m. in Room 147AB.
-- TAXUS IV five-year results. The Company will release final five-year
data from the TAXUS IV clinical trial, which evaluates the TAXUS
Express2 Paclitaxel-Eluting Coronary Stent System versus bare-metal
stents. This prospective, randomized, double-blind study has enrolled
1,314 patients at 73 U.S. sites. The results will be presented by Dr.
Ellis at 4:00 p.m. at an oral abstract session in Room 147AB. The
Company plans to issue a press release at this time.
Tuesday, October 23
-- CABERNET & BEACH Trial Results on Carotid Stenting. At 4:00 p.m.,
three-year follow-up results from the CABERNET and BEACH clinical
trials will be presented in an oral abstract session by L. Nelson
Hopkins, M.D., in Room 147AB. The CABERNET trial was designed to
evaluate the safety and efficacy of the Company's NexStent(R) Carotid
Stent System and FilterWire EZ(TM) Embolic Protection System, which
received FDA approval in 2006. BEACH is a prospective, single-arm,
multi-center trial designed to evaluate similar clinical outcomes of
the Company's Monorail(R) Carotid WALLSTENT(R) Endoprosthesis in
conjunction with the FilterWire EX(R) and FilterWire EZ(TM) Embolic
Protection Systems in the tre
|SOURCE Boston Scientific Corporation|
Copyright©2007 PR Newswire.
All rights reserved